-Study characteristics: 4700 patients. Mean age 72. Entry
BP 170/77 mm Hg. Study Completion: active 144/68 mm Hg, placebo 155/71 mm Hg. Entry potassium was 4.5mEq/L and fell by 0.3mEq/L more in the active arm.
-Upon SHEP termination at 4.5 yrs, the incidence of new onset DM was 12% in the chlorthalidone and 9.0% in the placebo arm.
-At 14.5 years, all cause mortality and cardiovascular mortality were lower among the chlorthalidone group.
-In the chlorthalidone arm, those who developed DM did not have more CV events compared to those who did not develop DM. Conversely, among placebo treated patients, those with developed DM had worse health outcomes than those who did not.